American Bio Medica (ABMC) 10-Q 12 Jun 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	Jun. 12, 2023
Cover [Abstract]
Entity Registrant Name	AMERICAN BIO MEDICA CORPORATION
Entity Central Index Key	0000896747
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Mar. 31, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Entity Common Stock Shares Outstanding		48,098,476
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	0-28666
Entity Incorporation State Country Code	NY
Entity Tax Identification Number	14-1702188
Entity Interactive Data Current	Yes
Entity Address Address Line 1	122 Smith Road
Entity Address City Or Town	Kinderhook
Entity Address State Or Province	NY
Entity Address Postal Zip Code	12106
Security 12b Title	Common Stock
Trading Symbol	ABMC
City Area Code	518
Local Phone Number	758-8158

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 68,000	$ 34,000
Accounts receivable, net of allowance for doubtful accounts of $2,000 at March 31, 2023 and at December 31, 2022	89,000	82,000
Inventory, net of allowance of $0 at March 31, 2023 and $235,000 at December 31, 2022	0	379,000
Employee retention credit receivable	202,000	202,000
Retention fund receivable-asset sale	300,000
Prepaid expenses and other current assets	0	72,000
Total current assets	659,000	769,000
Property, plant and equipment, net	0	466,000
Right of use asset - operating leases	0	13,000
Other assets	0	21,000
Total assets	659,000	1,269,000
Current liabilities
Accounts payable	572,000	760,000
Accrued expenses and other current liabilities	338,000	514,000
Right of use liability - operating leases	0	4,000
Wages payable	32,000	94,000
Current portion of long-term debt	175,000	2,230,000
Total current liabilities	1,117,000	3,602,000
Right of use liability - operating leases	0	6,000
Total liabilities	1,117,000	3,608,000
Stockholders' deficit:
Preferred stock; par value $.01 per share; 5,000,000 shares authorized, none issued and outstanding at March 31, 2023 and December 31, 2022	0	0
Common stock; par value $.01 per share; 75,000,000 shares authorized; 48,098,476 issued and outstanding at March 31, 2023 and at December 31, 2022	481,000	481,000
Additional paid-in capital	22,403,000	22,403,000
Deficit	(23,342,000)	(25,223,000)
Total stockholders' (deficit)	(458,000)	(2,339,000)
Total liabilities and stockholders' (deficit)	$ 659,000	$ 1,269,000

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Condensed Balance Sheets
Allowance for doubtful accounts receivable, current	$ 2,000	$ 2,000
Inventory, net of allowance	$ 0	$ 235,000
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	48,098,476	48,098,476
Common stock, shares outstanding	48,098,476	48,098,476

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Condensed Statements of Operations (Unaudited)
Net sales	$ 164,000	$ 351,000
Cost of goods sold	90,000	323,000
Gross profit	74,000	28,000
Operating expenses:
Research and development	28,000	22,000
Selling and marketing	20,000	42,000
General and administrative	238,000	295,000
Operating expenses	286,000	359,000
Operating loss	(212,000)	(331,000)
Other income/ (expense):
Loss on asset valuation	(921,000)	0
Other income - asset sale	3,035,000	0
Interest expense	(21,000)	(48,000)
Other non operating expenses	2,093,000	(48,000)
Net income / (loss) before tax	1,881,000	(379,000)
Income tax expense	0	0
Net income / (loss)	$ 1,881,000	$ (379,000)
Basic and diluted income / (loss) per common share	$ 0.04	$ (0.01)
Weighted average number of shares outstanding - basic & diluted	48,098,476	47,770,698

Statements of Changes in Stockh

Statements of Changes in Stockholders Deficit (Unaudited) - USD ($)	Total	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Balance, shares at Dec. 31, 2021		47,598,476
Balance, amount at Dec. 31, 2021	$ (944,000)	$ 476,000	$ 22,393,000	$ (22,813,000)
Shares issued in connection with Landmark consulting agreement, shares		500,000
Shares issued in connection with Landmark consulting agreement, amount	15,000	$ 5,000	10,000
Net loss	(379,000)			(379,000)
Balance, shares at Mar. 31, 2022		48,098,476
Balance, amount at Mar. 31, 2022	(1,308,000)	$ 481,000	22,403,000	(24,192,000)
Balance, shares at Dec. 31, 2022		48,098,476
Balance, amount at Dec. 31, 2022	(2,339,000)	$ 481,000	22,403,000	(25,223,000)
Net loss	1,881,000			1,881,000
Balance, shares at Mar. 31, 2023		48,098,476
Balance, amount at Mar. 31, 2023	$ (458,000)	$ 481,000	$ 22,403,000	$ (23,342,000)

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net income / (loss)	$ 1,881,000	$ (379,000)
Adjustments to reconcile net income / (loss) to net cash used in operating activities:
Depreciation and amortization	8,000	13,000
Asset Sale to Healgen	(2,114,000)	0
Provision for bad debt	0	(1,000)
Consulting fee paid with restricted stock	0	15,000
Changes in:
Accounts receivable	(7,000)	186,000
Inventory	0	24,000
Prepaid expenses and other current assets	83,000	(11,000)
Right of use asset	0	9,000
Accounts payable	24,000	161,000
Accrued expenses and other current liabilities	(176,000)	(17,000)
Right of use liability	0	(9,000)
Wages payable	(62,000)	(4,000)
Net cash used in operating activities	(363,000)	(13,000)
Cash Flows from investing activities
Business Sale, net proceeds	247,000	0
Net cash provided by investing activities	247,000	0
Cash flows from financing activities:
Payments on debt financing	(100,000)	0
Proceeds from debt financing	250,000	0
Proceeds from lines of credit	0	462,000
Payments on lines of credit	0	(547,000)
Net cash provided by / (used in) financing activities	150,000	(85,000)
Net change in cash and cash equivalents	34,000	(98,000)
Cash and cash equivalents - beginning of period	34,000	115,000
Cash and cash equivalents - end of period	68,000	17,000
Non-Cash transactions:
Non-Cash transactions: Consulting fee paid with restricted stock	0	15,000
Cash paid for interest	$ 41,000	$ 46,000

Basis of Reporting

Basis of Reporting	3 Months Ended
	Mar. 31, 2023
Basis of Reporting
Basis of Reporting	Note A - Basis of Reporting The accompanying unaudited interim condensed financial statements of American Bio Medica Corporation (the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Regulation S-X. Accordingly, these unaudited interim condensed financial statements do not include all information and footnotes required by U.S. GAAP for complete financial statement presentation. These unaudited interim condensed financial statements should be read in conjunction with audited financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. In the opinion of management, the interim condensed financial statements include all normal, recurring adjustments which are considered necessary for a fair presentation of the financial position of the Company at March 31, 2023, and the results of operations and cash flows for the three month periods ended March 31, 2023 (the “First Quarter 2023”) and March 31, 2022 (the “First Quarter 2022”). Operating results for the First Quarter 2023 are not indicative of results that will be reported for the year ending December 31, 2023 as the Company sold substantially all of its assets on February 28, 2023 to Healgen Scientific, LLC (“Healgen”). Amounts at December 31, 2022 are derived from audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. During the First Quarter 2023, there were no significant changes to the Company’s critical accounting policies, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The preparation of these interim condensed financial statements requires the Company to make estimates and judgments that affect the reported amounts of liabilities, expenses, and related disclosure of contingent liabilities. On an on-going basis, the Company evaluates estimates, including those related to bad debts, income taxes, warranty obligations, contingencies and litigation. The Company bases estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. These unaudited interim condensed financial statements have been prepared assuming that the Company will continue as a going concern and, accordingly, do not include any adjustments that might result from the outcome of this uncertainty. The independent registered public accounting firm’s report on the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, contained an explanatory paragraph regarding the Company’s ability to continue as a going concern. As of the date of this report, the Company’s current cash balances and amounts expected from its receivables (including the Employee retention Credit receivable and the retention (escrow) proceeds from the asset sale) may not be sufficient to fund the Company through May 2024. The Company’s credit facilities with Cherokee Financial, LLC (“Cherokee”) were paid in full with proceeds from the asset sale on February 28, 2023. Recently Adopted Accounting Standards ASU 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations, ASU 2016-13, Financial Instruments—Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments Accounting Standards Issued; Not Yet Adopted ASU 2022-03, Fair Value Measurement (Topic 820), Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions Any other new accounting pronouncements recently issued, but not yet effective, have been reviewed and determined to be not applicable or were related to technical amendments or codification. As a result, the adoption of such new accounting pronouncements, when effective, is not expected to have a material effect on the Company’s financial position or results of operations.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2023
Inventory
Inventory	Note B – Inventory Inventory is comprised of the following: March 31, 2023* December 31, 2022 Raw Materials $ 0 $ 444,000 Work In Process 0 110,000 Finished Goods 0 60,000 Allowance for slow moving and obsolete inventory 0 (235,000 ) $ 0 $ 379,000 *On February 28, 2023, the Company sold substantially all of its assets to Healgen, including its inventory.

Property, Plant and Equipment

Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment
Property, Plant and Equipment	Note C – Property, Plant and Equipment Property, plant and equipment, is comprised of the following: March 31, 2023* December 31, 2022 Land $ 0 $ 102,000 Buildings and improvements 0 1,352,000 Manufacturing and warehouse equipment 0 2,110,000 Office equipment (incl. furniture and fixtures) 0 412,000 0 3,976,000 Less accumulated depreciation 0 (3,510,000 ) $ 0 $ 466,000 *On February 28, 2023, the Company sold substantially all of its assets to Healgen, including its property, plant and equipment.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2023
Accrued Expenses
Accrued Expenses	Note D – Accrued Expenses Accrued expenses and other current liabilities consisted of the following as of March 31, 2023 and December 31, 2022: March 31, 2023 December 31, 2022 Accounting fees $ 16,000 $ 87,000 Interest payable 20,000 39,000 Accounts receivable credit balances 0 1,000 Sales tax payable 188,000 188,000 Deferred compensation 114,000 109,000 Other current liabilities 0 90,000 $ 338,000 $ 514,000

Net Income (Loss) Per Common Sh

Net Income (Loss) Per Common Share	3 Months Ended
	Mar. 31, 2023
Net Income (Loss) Per Common Share
Net Income / (Loss) Per Common Share	Note E – Net Income / (Loss) Per Common Share Basic net income / (loss) per common share is calculated by dividing the net income / (loss) by the weighted average number of outstanding common shares during the period. Diluted net income / (loss) per common share includes the weighted average dilutive effect of stock options and warrants. When the Company has a loss, option and warrants are not included as they would be anti-dilutive. In the three months ended March 31, 2023, although the Company had net income, there were no options in the money at March 31, 2023. Potential common shares outstanding as of March 31, 2023 and 2022: March 31, 2023 March 31, 2022 Options 1,690,000 1,937,000 Total 1,690,000 1,937,000

LitigationLegal Matters

LitigationLegal Matters	3 Months Ended
	Mar. 31, 2023
LitigationLegal Matters
Litigation/Legal Matters	Note F – Litigation/Legal Matters From time to time, the Company may be involved in immaterial legal proceedings in connection with matters that arise during the normal course of business. While the ultimate outcome of any such immaterial litigation cannot be predicted, if the Company is unsuccessful in defending any such litigation, the resulting financial losses are not expected to have a material adverse effect on the financial position, results of operations or cash flows of the Company.

Debt

Debt	3 Months Ended
	Mar. 31, 2023
Debt
Debt	Note G – Debt The Company’s Line of Credit and Debt consisted of the following as of March 31, 2023 and December 31, 2022: March 31, 2023 December 31, 2022 Loan and Security Agreement with Cherokee Financial, LLC $ 0 $ 1,000,000 2019 Term Loan with Cherokee Financial, LLC: 0 240,000 November 2020 Shareholder Note: 50,000 50,000 December 2021 Shareholder Notes: 125,000 225,000 September 2022 Healgen Loan & Promissory Note 0 715,000 Total Debt $ 175,000 $ 2,230,000 Current portion $ 175,000 $ 2,230,000 LOAN AND SECURITY AGREEMENT (“LSA”) WITH CHEROKEE FINANCIAL, LLC (“CHEROKEE”) On March 26, 2015, the Company entered into a LSA with Cherokee (the “Cherokee LSA”) in the amount of $1,200,000, which was collateralized by a first security interest in real estate and machinery and equipment. The Cherokee LSA reached maturity on February 15, 2020 with a balance of $900,000 (after 4 principal reduction payments of $75,000 each were made over the course of the initial term). In February 2020, the Cherokee LSA was extended for one year, or until February 15, 2021. No terms of the facility were changed under the February 2020 extension. In February 2021, the Cherokee LSA was further extended for another year, or until February 15, 2022 (the “February 2021 Extension”). Under the February 2021 Extension, the principal of the Cherokee LSA was increased to $1,000,000 to include a $100,000 penalty that was due as a result of the Company being unable to pay back the principal balance to Cherokee on February 15, 2021. The annual interest rate on the Cherokee LSA was also increased to a fixed rate of 10% (the prior fixed rate was 8%) plus a 1% annual oversight fee (that remained unchanged). Interest and the oversight fee were still due quarterly. Under the terms of the February 2021 Extension, if the Company didn’t pay off the principal on or before February 15, 2022, Cherokee could charge an 8% delinquent fee on the principal balance ($1,000,000) on February 15, 2022. The Company was not able to pay off the facility on February 15, 2022; however, on June 14, 2022 Cherokee agreed that they would defer the principal amounts due under the Cherokee LSA until February 15, 2023 and that any applicable penalties would also be deferred as long as the Company remained current on the quarterly interest payments. On February 28, 2023, with proceeds from the Asset Sale to Healgen, the Company paid all amounts due to Cherokee under the LSA for principal and interest. The Company recognized $13,000 in interest expense related to the Cherokee LSA in the First Quarter 2023 and $25,000 in interest expense related to the Cherokee LSA in the First Quarter 2022 As of March 31, 2023 and December 31, 2022, the balance of the Cherokee LSA was $0 and $1,000,000, respectively. 2019 TERM LOAN WITH CHEROKEE In February 2019, the Company entered into an agreement with Cherokee under which Cherokee provided the Company with a loan in the amount of $200,000 (the “2019 Cherokee Term Loan”). The annual interest rate under the 2019 Cherokee Term Loan was 18% (fixed) paid quarterly in arrears. In February 2020, the 2019 Cherokee Term Loan was extended for one year, or until February 15, 2021. No terms of the facility were changed under the February 2020 extension. The Company incurred a penalty in the amount of $20,000 which was added to the principal balance of the 2019 Cherokee Term Loan; bringing the principal to $220,000. In February 2021, the 2019 Cherokee Term Loan was further extended to February 15, 2022. Under the terms of this additional extension, the 2019 Cherokee Term Loan was increased to $240,000 to include a $20,000 penalty that was due as a result of the Company being unable to pay back the principal balance to Cherokee on February 15, 2021. In addition, if the Company didn’t pay off the principal on or before February 15, 2022, Cherokee could charge an 8% delinquent fee on the principal balance ($240,000) on February 15, 2022. The Company was not able to pay off the facility on February 15, 2022; however, on June 14, 2022 Cherokee agreed that they would defer the principal amounts due under the 2019 Cherokee Term Loan until February 15, 2023 and that any applicable penalties would also be deferred as long as the Company remained current on the quarterly interest payments. The Company recognized $4,000 in interest expense in the First Quarter 2023 and $11,000 in interest expense in the First Quarter 2022. The Company paid all principal and interest due to Cherokee on February 28, 2023 with proceeds from the Asset Sale to Healgen. The balance of the 2019 Cherokee Term Loan was $0 at March 31, 2023 and $240,000 at December 31, 2022. NOVEMBER 2020 TERM LOAN On November 4, 2020, the Company entered into a loan agreement with an individual shareholder in the principal amount of $50,000. There were no expenses related to the term loan and the interest rate is 7%. The first interest only payment was made on February 4, 2021 and the final interest payment and principal was due on May 4, 2021. On May 4, 2021, the Company extended this loan for another 6 months, or until November 4, 2021. The interest rate and all other terms of the note remained unchanged under this extension. On November 4, 2021, the November 2020 Term Loan was extended again. Under this extension, the principal was due on November 4, 2022. The last interest payment made to the shareholder was in November 2021 and was for the period of August 5, 2021 through November 4, 2021. The shareholder agreed to defer the quarterly interest payments due on the extended facility. The facility was further extended on November 4, 2022, under the same terms and conditions, for another 6 months, or until May 4, 2023. The Company recognized less than $1,000 in interest expense related to the November 2020 Term Loan in the First Quarter 2023 and $1,000 in interest expense in the First Quarter 2022. The balance on the November 2020 Term Loan was $50,000 at March 31, 2023 and December 31, 2022. (See Note M – Subsequent Events for more information on the November 2020 Term Loan) DECEMBER 2021 SHAREHOLDER LOANS On December 14, 2021, the Company entered into Loan Agreements with two non-affiliated shareholders resulting in gross (and net) proceeds of $75,000 as there were no costs associated with the loans. Interest on the loans was 7% per annum until principal and interest were due in full, or until June 15, 2022. The first interest payments were due March 15, 2022 and payment of final interest and principal was due June 15, 2022. One of the loans (in the amount of $25,000) was paid in full on June 13, 2022 along with the final interest payment due. On April 6, 2022, the Company amended the loan with the other non-affiliated shareholder. This amendment (No.1; hereinafter referred to in this paragraph as “Amendment No. 1”) increased the principal due to the shareholder by $25,000; bringing their total principal to $75,000. No other terms of the loan were changed under Amendment No. 1. On April 14, 2022, the loan was amended again (under Amendment No. 2; hereinafter referred to in this paragraph as “Amendment No. 2”) increasing the principal again by $50,000; bringing their total principal to $125,000. No other terms of the loan were changed under Amendment No. 2. On May 11, 2022, the loan was amended again (under Amendment No. 3; hereinafter referred to in this paragraph as “Amendment No. 3”) increasing the principal again by $75,000; bringing their total principal to $200,000. The loan was further amended to include a specific payment schedule based on receipt of anticipated ERC refunds. On June 13, 2022, the Company made a principal reduction payment to this shareholder in the amount of $25,000 from proceeds from the ERC refund received on June 2, 2022; bringing the principal amount owed on the loan to $175,000. On July 13, 2022, the loan was amended again (under Amendment No. 4; hereinafter referred to in this paragraph as “Amendment No. 4”) increasing the principal by $25,000; bringing their total principal to $200,000 again. The loan agreement was also amended to revise the maturity date from June 15, 2022 to no specific maturity date. On September 13, 2022, the loan was amended again (under Amendment No. 5; hereinafter referred to in this paragraph as “Amendment No. 5”) increasing the principal by $25,000; bringing their total principal to $225,000 again. On September 28, 2022, the shareholder provided the Company with additional funds, $40,000, under this loan with the understanding that the amount would be paid back once the Healgen Loan funds were received and there would be no interest charged on this additional amount. This increased the amount due to the shareholder under the facility to $265,000. The Company did pay this additional amount in full on October 4, 2022; bringing the balance of the loan back to $225,000. The Company incurred $4,000 in interest expense related to these loans in the First Quarter 2023 and $1,000 in interest expense related to these loans in the First Quarter 2022. The balance on these loans was $125,000 on March 31, 2023 and $225,000 at December 31, 2022. (See Note M – Subsequent Events for more information on the December 2021 Shareholder Loans) SEPTEMBER 2022 HEALGEN LOAN & PROMISSORY NOTE On September 28, 2022, the Company entered into a Loan and Promissory with Healgen Scientific Limited Liability Company (the “Healgen Loan”) at a fixed rate of 1% per month, (compounded monthly) and received initial gross/net proceeds of $40,000 and subsequent gross/net proceeds of $360,000; for a total of $400,000. The Company utilized $34,000 of the loan proceeds to pay off the Crestmark Line of Credit and the balance was used for working capital. The Healgen Loan was collateralized by a first security interest in the Company’s receivables, inventory, and all other assets with the exception of those assets already encumbered. The first payment under the Healgen Loan was due on January 28, 2023 and was in the amount of $140,000. The Healgen Loan was amended on November 15, 2022 to increase the principal due under the loan to $700,000. Under this first amendment, the loan maturity date was extended to April 15, 2023 and the first payment date was extended to February 15, 2023 and changed to $246,000. The Healgen loan was amended again on December 19, 2022 to increase the principal due under the loan to $715,000. Under this second amendment, the amount of the first payment was changed to $251,000 with payments of the same amount due on March 15, 2023 and April 15, 2023. The Healgen Loan was amended again on January 6, 2023 to increase the principal due under the loan to $815,000. Under this third amendment, the amount of the first payment (due February 15, 2023) was changed to $286,000 with payments of the same amount due on March 15, 2023 and April 15, 2023. No other terms of the Healgen Loan were changed. The Healgen Loan was amended again on February 9, 2023 to increase the principal due under the loan to $965,000. Under this fourth amendment, the amount of the first payment (due February 15, 2023) was changed to $337,000 with payments of the same amount due on March 15, 2023 and April 15, 2023. No other terms of the Healgen Loan were changed. On February 28, 2023, with proceeds from the Asset Sale to Healgen, the Company made a payment in the amount of $965,000 to Healgen for all principal due under the Healgen Loan. Healgen waived all interest due under the Healgen Loan. The balance on the Healgen Loan was $0 at March 31, 2023 and $715,000 at December 31, 2022. OTHER DEBT INFORMATION In addition to the debt indicated previously, previous debt facilities (paid in full via refinance or conversion into equity) had financial impact on the First Quarter 2022. More specifically: LINE OF CREDIT WITH CRESTMARK BANK (“CRESTMARK”) On June 29, 2015, the Company entered into a Loan and Security Agreement (“LSA”) with Crestmark related to a revolving line of credit (the “Crestmark LOC”). The Crestmark LOC was used for working capital and general corporate purposes. Upon completion of the initial 5 year term, the Crestmark LOC automatically renewed for additional one (1) year terms unless notice of termination from the Company was received by Crestmark not less than sixty (60) days prior to the end of the renewal term. On September 29, 2022, the Company made a payment to Crestmark in the amount of $34,000 which paid off the balance on the Crestmark LOC. The Company incurred $0 in interest expense in the First Quarter 2023 and $10,000 in interest expense in the First Quarter 2022.

Employee Retention Credit

Employee Retention Credit	3 Months Ended
	Mar. 31, 2023
Employee Retention Credit
Employee Retention Credit	NOTE H – Employee Retention Credit The employee retention credit (“ERC”), as originally enacted on March 27, 2020 by the CARES Act, was a refundable tax credit against certain employment taxes equal to 50% of the qualified wages an eligible employer paid to employees and allowed claims through December 31, 2021 by eligible employers who retained employees during the Covid-19 pandemic. However, in November 2021, the ERC was terminated as of September 30, 2021 instead of December 31, 2021. The maximum qualified wages for each employee under the ERC was $10,000 per quarter. Also, because the Company has 100 or fewer full-time employees, health plan expenses borne by the Company could also be included as qualified wages in addition to salary. In August 2021, the Company’s payroll service provider processed and mailed a Form 941-X to claim a refund in the amount of $202,000 on qualified wages paid in the first quarter of 2021. Due to a change in the Form 941-X, the Company’s payroll service provider did not process and mail its Form 941-X to claim a refund in the amount of $198,000 on qualified wages paid in the second quarter of 2021 until October 28, 2021. The Company was informed that the IRS did not have record of receiving the Company’s Form 941-X for the first quarter of 2021 (which was mailed by the Company’s service provider in August 2021). The Company re-sent the Form 941-X for the first quarter of 2021 via overnight service on December 31, 2021 and the IRS received it on January 5, 2022. This lack of receipt resulted in a delay in receiving the expected refund in the amount of $202,000. On June 2, 2022, the Company received a refund for the second quarter of 2021 in the amount of $199,000. This amount represents the $198,000 claimed as a refund and $1,000 in interest. The Company has had a number of discussions with the IRS and has been given a number of time frames in which the refund for the first quarter of 2021 could be expected. As of March 31, 2023, the Company had not yet received the refund. (See Note M – Subsequent Events for updated information on the ERC refund)

Asset Sale to Healgen

Asset Sale to Healgen	3 Months Ended
	Mar. 31, 2023
Asset Sale to Healgen
Asset Sale to Healgen	Note I – Asset Sale to Healgen Over the last several years, the Company has retained financial consultants to seek out alternative solutions; most recently in early Fiscal 2022. The consultants were seeking solutions including but not limited to potential mergers, acquisitions, investment in the Company, and strategic relationships. Simultaneously, the Company’s management was seeking alternative solutions and began discussions with Healgen. With the current financial condition of the Company, the Company was not able to find a suitable alternative apart from the Asset Sale to Healgen. After carefully weighing the facts and circumstances associated with the Asset Sale to Healgen as well as alternative courses of action, the Company’s Board of Directors (the “Board”) unanimously concluded that the proposed sale of substantially all of the Company’s assets was the best available alternative to maximize value for shareholders. The Board believes the Company’s status as a fully reporting public company is an asset which may be sufficiently attractive to induce others to enter into business combinations with the Company. The Company is exploring strategic transactions which may result in entering into a new line of business (subject to specific competitive limitations under the Asset Sale to Healgen). The Company believes strategic acquisitions using the Company’s publicly traded stock as transaction consideration could enhance shareholder value. Nonetheless, the Board may later determine to dissolve the Company and distribute any remaining assets to the Company’s shareholders if the Company is unable to make any strategic acquisitions or enter into any strategic transactions. On December 19, 2022, the Company entered into an Asset Purchase Agreement (“APA”) with Healgen, pursuant to which the Company agreed, subject to the approval of its shareholders, to sell substantially all of the Company’s operating assets (excluding its cash, accounts receivables arising prior to the closing date, and certain other assets). The Company submitted the Asset Sale to Healgen to a shareholder vote via a preliminary Proxy Statement filed on December 22, 2022. On January 5, 2023, the Company filed an amendment to its Preliminary Proxy Statement and on January 11, 2023, the Company filed its Definitive Proxy Statement with the SEC. On February 15, 2023, the Company held the 2023 Special Meeting of Shareholders (the “Special Meeting”) at the Company’s corporate offices in Kinderhook, New York, at which a quorum (27,863,899 shares of common stock of the 47,098,476 shares of common stock outstanding) was present in person or represented by proxy. Approval of the Asset Sale to Healgen required the affirmative vote of the holders of a majority of the outstanding shares of the Company’s common stock (par value $0.01). 26,381,832, or 54.84% of the total outstanding shares of the Company, voted in favor of the Asset Sale to Healgen. 1,476,077, or 3.06% of the total outstanding shares, voted against the Asset Sale to Healgen. 5,990, or 0.01% of the total shares outstanding, withheld voting on the Asset Sale to Healgen. Given the majority of total outstanding shares voted in favor of the Asset Sale to Healgen, the Asset Sale to Healgen was approved. On February 28, 2023, the Company completed the Asset Sale to Healgen and disposition of substantially all of the Company’s assets. In connection with the closing of the Asset Sale to Healgen, and in accordance with the terms of the Asset Purchase Agreement, Healgen paid an aggregate purchase price of $3 million (“Purchase Price”). $300,000 of the Purchase Price is being held back in a retention fund to cover potential indemnification claims during the six months following the close. Net proceeds in the amount of $247,000 were received by the Company after satisfaction of 1) a loan with Healgen in the amount of $965,000, 2) the Cherokee LSA, (totaling $1,031,000 for principal and interest through February 27, 2023), 3) the 2019 Cherokee Term Loan (totaling $252,000 for principal and interest through February 27, 2023), 4) delinquent property related taxes in the amount of $193,000 and 5) $12,000 for current property related taxes.

Stock Options and Warrants

Stock Options and Warrants	3 Months Ended
	Mar. 31, 2023
Stock Options and Warrants
Stock Options and Warrants	NOTE J – Stock Options and Warrants The Company has two non-statutory stock option plans, the Fiscal 2001 Non-statutory Stock Option Plan (the “2001 Plan”) and the 2013 Equity Compensation Plan (the “2013 Plan”). Both plans have been adopted by the Board of Directors and approved by shareholders. Both the 2001 Plan and the 2013 Plan have options available for future issuance. Any common shares issued as a result of the exercise of stock options would be new common shares issued from our authorized issued shares. During the First Quarter 2023 and the First Quarter 2022, the Company issued 0 options to purchase shares of common stock. Stock option activity for the First Quarter 2023 and the First Quarter 2022 is summarized as follows (the figures contained within the tables below have been rounded to the nearest thousand): First Quarter 2023 First Quarter 2022 Shares Weighted Average Exercise Price Aggregate Intrinsic Value as of March 31, 2023 Shares Weighted Average Exercise Price Aggregate Intrinsic Value as of March 31, 2022 Options outstanding at beginning of year 1,736,000 $ 0.12 1,937,000 $ 0.13 Granted 0 NA 0 NA Exercised 0 NA 0 NA Cancelled/expired 46,000 $ 0.26 0 NA Options outstanding at end of quarter 1,690,000 $ 0.12 $ 0 1,937,000 $ 0.13 $ 0 Options exercisable at end of quarter 1,690,000 $ 0.12 1,937,000 $ 0.13 The Company recognized $0 in share based payment expense in the First Quarter 2023 and the First Quarter 2022. At March 31, 2023, there was $0 of unrecognized share based payment expense related to stock options.

Changes in Stockholders Deficit

Changes in Stockholders Deficit	3 Months Ended
	Mar. 31, 2023
Changes in Stockholders Deficit
Changes in Stockholders' Deficit	NOTE K – Changes in Stockholders’ Deficit LANDMARK CONSULTING AGREEMENT On March 7, 2022, the Company entered into a Financial Advisory Agreement (the “Agreement”) with Landmark Pegasus, Inc. (‘Landmark”). The Agreement provided that Landmark would provide certain financial advisory services for a minimum period of 3 months (which period commenced on February 28, 2022), and as consideration for these services, the Company would pay Landmark (a) a retainer fee consisting of 500,000 restricted shares of common stock and a warrant to purchase 2.75 million shares of the Company’s common stock at a strike price equal to the average closing price of the Company’s common shares for the 30 days preceding the Agreement, or $0.035 per share, resulting in gross proceeds to the Company in the amount of $96,250. The warrant would vest upon the closing of a transaction involving Landmark or upon the invocation of a “Breakup Fee”. In a subsequent amendment, the terms of the warrant were changed to reflect that the warrant would be issued immediately preceding the closing of a transaction involving Landmark or immediately upon the invocation of the Breakup Fee. In each case, the warrant would vest immediately (i.e. the warrant would be 100% immediately exercisable). The Breakup Fee would be invoked upon the generation of a specific transaction to ABMC which meets certain criteria agreed upon by both the Company and Landmark; which transaction is then rejected by the Company. The Company would also pay to Landmark a “Success Fee” for the consummation of a transaction closing during the term of the Agreement and for 12 months thereafter, between the Company and any party first introduced to the Company by Landmark, or with any party the Company has specifically requested Landmark’s assistance with the transaction. Upon invocation of the Breakup Fee or payment of the Success Fee, the Company would also issue an additional 250,000 restricted shares of the Company’s common stock. In the event that the Company consummated a transaction involving the provision of services to any party introduced to the Company by Landmark or with any party the Company has specifically requested Landmark’s assistance with, the Company would pay Landmark 10% of any revenues received from the transaction, unless this percentage is modified by both the Company and Landmark in writing. There is no material relationship between the Company and Landmark, other than with respect to the Agreement. Apart from the initial 500,000 restricted common shares, no additional stock was issued to Landmark and no further amounts were paid to Landmark.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Taxes
Income Taxes	Note L- Income Taxes The Company follows ASC 740 “Income Taxes” (“ASC 740”) which prescribes the asset and liability method whereby deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted laws and tax rates that will be in effect when the differences are expected to reverse. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance for any tax benefits that are not expected to be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. Under ASC 740, tax benefits are recorded only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon ultimate settlement. Unrecognized tax benefits are tax benefits claimed in the Company’s tax returns that do not meet these recognition and measurement standards. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. With regards to the use of net losses incurred for 2018 and later, such net operating losses have no expiration, while taxable income can only be offset up to 80% of taxable income. Net operating losses incurred prior to 2018 may be fully utilized to offset taxable income. A reconciliation of the U.S. Federal statutory income tax rate to the effective income tax rate is as follows: Quarter Ended March 31, 2023 Quarter Ended March 31, 2022 Tax expense at federal statutory rate (21%) (21%) State tax expense, net of federal tax effect 0 % 0 % Increase in valuation allowance 21 % 21 % Effective income tax rate (0%) (0%) Significant components of the Company’s deferred income tax assets are as follows: March 31, 2023 December 31, 2022 13, Inventory allowance $ 0 $ 61,000 Allowance for doubtful accounts 1,000 1,000 Stock based compensation 138,000 149,000 Deferred wages payable 30,000 21,000 Depreciation – Property, Plant & Equipment 0 (19,000 ) Research and development credits 26,000 24,000 Net operating loss carry-forward 2,482,000 2,972,000 Total gross deferred income tax assets 2,677,000 3,209,000 Less deferred income tax assets valuation allowance (2,677,000 ) (3,209,000 ) Net deferred income tax assets $ 0 0 The valuation allowance for net deferred income tax assets as of March 31, 2023 and December 31, 2022 was $2,677,000 and $3,209,000, respectively. The net change in the valuation allowance was $532,000 at March 31, 2023 and $91,000 at March 31, 2022. The Company believes that it is more likely than not that the net deferred tax assets will not be realized. As of March 31, 2023, the prior three years remain open for examination by the federal or state regulatory agencies for purposes of an audit for tax purposes. At March 31, 2023, the Company had Federal net operating loss carry-forwards for income tax purposes of approximately $11,427,000 and research and development credits of $26,000. The Company’s net operating loss carry-forwards began to expire in 2022 and continue to expire through 2038. Net operating losses incurred from 2018 to date have no expiration. In assessing the reliability of deferred income tax assets, management considers whether or not it is more likely than not that some portion or all deferred income tax assets will be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the projected future taxable income and tax planning strategies in making this assessment. The Company’s ability to utilize the operating loss carry-forwards and research and development credits may be subject to an annual limitation in future periods pursuant to Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, if future changes in ownership occur. The Company recognizes potential interest and penalties related to income tax positions as a component of the provision for income taxes on operations. The Company does not anticipate that total unrecognized tax benefits will materially change in the next twelve months.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events
Subsequent Events	Note M – Subsequent Events ERC Refund The Company has been expecting an ERC refund in the amount of $202,000. On April 17, 2023, the Company received payments in the amount of $156,000 and $2,000 from the IRS. There was not any communication with either of the payments. As of the date of this report, the Company is making efforts to speak with the IRS to determine the reason behind the lower refund being received and to determine if additional payments can be expected. November 2020 Term Loan Upon receipt of the payment from the IRS, the Company paid the principal balance due ($50,000) on this shareholder loan. December 2021 Shareholder Loan Upon receipt of the payment from the IRS, the Company made a payment in the amount of $25,000 on this shareholder loan. As of the date of this report, the balance on the December 2021 Shareholder Loan is $175,000. Current Salary owed to Melissa Waterhouse Upon receipt of the payment from the IRS, the Company made a payment in the amount of $32,000 to Melissa Waterhouse to pay current salary owed. As of the date of this report, the amount due to Melissa Waterhouse for deferred compensation is $92,000. Ms. Waterhouse is also owed $12,000 for consulting services from March 2023 through May 2023.

Basis of Reporting (Policies)

Basis of Reporting (Policies)	3 Months Ended
	Mar. 31, 2023
Basis of Reporting
Recently Adopted Accounting Standards	ASU 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations, ASU 2016-13, Financial Instruments—Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments
Accounting Standards Issued Not Yet Adopted	ASU 2022-03, Fair Value Measurement (Topic 820), Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions Any other new accounting pronouncements recently issued, but not yet effective, have been reviewed and determined to be not applicable or were related to technical amendments or codification. As a result, the adoption of such new accounting pronouncements, when effective, is not expected to have a material effect on the Company’s financial position or results of operations.

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2023
Inventory
Inventory	March 31, 2023* December 31, 2022 Raw Materials $ 0 $ 444,000 Work In Process 0 110,000 Finished Goods 0 60,000 Allowance for slow moving and obsolete inventory 0 (235,000 ) $ 0 $ 379,000

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment
Property, plant and equipment	March 31, 2023* December 31, 2022 Land $ 0 $ 102,000 Buildings and improvements 0 1,352,000 Manufacturing and warehouse equipment 0 2,110,000 Office equipment (incl. furniture and fixtures) 0 412,000 0 3,976,000 Less accumulated depreciation 0 (3,510,000 ) $ 0 $ 466,000

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2023
Accrued Expenses
Accrued Expenses	March 31, 2023 December 31, 2022 Accounting fees $ 16,000 $ 87,000 Interest payable 20,000 39,000 Accounts receivable credit balances 0 1,000 Sales tax payable 188,000 188,000 Deferred compensation 114,000 109,000 Other current liabilities 0 90,000 $ 338,000 $ 514,000

Net Income (Loss) Per Common _2

Net Income (Loss) Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2023
Net Income (Loss) Per Common Share
Net Income / (Loss) Per Common Share	March 31, 2023 March 31, 2022 Options 1,690,000 1,937,000 Total 1,690,000 1,937,000

DEBT (Tables)

DEBT (Tables)	3 Months Ended
	Mar. 31, 2023
Debt
Debt	March 31, 2023 December 31, 2022 Loan and Security Agreement with Cherokee Financial, LLC $ 0 $ 1,000,000 2019 Term Loan with Cherokee Financial, LLC: 0 240,000 November 2020 Shareholder Note: 50,000 50,000 December 2021 Shareholder Notes: 125,000 225,000 September 2022 Healgen Loan & Promissory Note 0 715,000 Total Debt $ 175,000 $ 2,230,000 Current portion $ 175,000 $ 2,230,000

Stock Options and Warrants (Tab

Stock Options and Warrants (Tables)	3 Months Ended
	Mar. 31, 2023
Stock Options and Warrants
Stock option/warrant activity	First Quarter 2023 First Quarter 2022 Shares Weighted Average Exercise Price Aggregate Intrinsic Value as of March 31, 2023 Shares Weighted Average Exercise Price Aggregate Intrinsic Value as of March 31, 2022 Options outstanding at beginning of year 1,736,000 $ 0.12 1,937,000 $ 0.13 Granted 0 NA 0 NA Exercised 0 NA 0 NA Cancelled/expired 46,000 $ 0.26 0 NA Options outstanding at end of quarter 1,690,000 $ 0.12 $ 0 1,937,000 $ 0.13 $ 0 Options exercisable at end of quarter 1,690,000 $ 0.12 1,937,000 $ 0.13

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2023
Income Taxes
Effective income tax rate reconciliation	Quarter Ended March 31, 2023 Quarter Ended March 31, 2022 Tax expense at federal statutory rate (21%) (21%) State tax expense, net of federal tax effect 0 % 0 % Increase in valuation allowance 21 % 21 % Effective income tax rate (0%) (0%)
Deferred tax assets and liabilities	March 31, 2023 December 31, 2022 13, Inventory allowance $ 0 $ 61,000 Allowance for doubtful accounts 1,000 1,000 Stock based compensation 138,000 149,000 Deferred wages payable 30,000 21,000 Depreciation – Property, Plant & Equipment 0 (19,000 ) Research and development credits 26,000 24,000 Net operating loss carry-forward 2,482,000 2,972,000 Total gross deferred income tax assets 2,677,000 3,209,000 Less deferred income tax assets valuation allowance (2,677,000 ) (3,209,000 ) Net deferred income tax assets $ 0 0

Inventory (Details)

Inventory (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Inventory
Raw materials	$ 0	$ 444,000
Work in process	0	110,000
Finished goods	0	60,000
Allowance for slow moving and obsolete inventory	0	(235,000)
Inventory, net	$ 0	$ 379,000

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment
Land	$ 0	$ 102,000
Buildings and improvements	0	1,352,000
Manufacturing and warehouse equipment	0	2,110,000
Office equipment (incl. furniture and fixtures)	0	412,000
Property, plant and equipment, gross	0	3,976,000
Less accumulated depreciation	0	(3,510,000)
Property, plant and equipment, net	$ 0	$ 466,000

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Accrued Expenses
Accounting fees	$ 16,000	$ 87,000
Other current liabilities	0	90,000
Accrued expenses	338,000	514,000
Interest payable	20,000	39,000
Accounts receivable credit balances	0	1,000
Sales tax payable	188,000	188,000
Deferred compensation	$ 114,000	$ 109,000

Net Income (Loss) Per Common _3

Net Income (Loss) Per Common Share (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Options	1,690,000	1,937,000
Equity Option [Member]
Options	1,690,000	1,937,000

Debt (Details)

Debt (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Total debt, net	$ 175,000	$ 2,230,000
Current portion	175,000	2,230,000
Loan and Security Agreement with Cherokee Financial, LLC
Long-term debt, gross	0	1,000,000
2019 Term Loan with Cherokee Financial, LLC
Long-term debt, gross	0	240,000
November 2020 Shareholder Note
Long-term debt, gross	50,000	50,000
December 2021 Shareholder Notes
Long-term debt, gross	125,000	225,000
September 2022 Healgen Loan & Promissory note
Long-term debt, gross	$ 0	$ 715,000

Debt (Details Narrative)

Debt (Details Narrative) - USD ($)											1 Months Ended									3 Months Ended
	Feb. 09, 2023	Jan. 06, 2023	Sep. 13, 2022	Jul. 13, 2022	Jun. 13, 2022	May 11, 2022	Apr. 14, 2022	Apr. 06, 2022	Dec. 14, 2021	Nov. 04, 2020	Feb. 28, 2023	Dec. 19, 2022	Nov. 15, 2022	Sep. 28, 2022	Feb. 15, 2022	Feb. 28, 2021	Feb. 15, 2021	Feb. 28, 2019	Jun. 29, 2015	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Sep. 29, 2022	Dec. 31, 2021	Mar. 26, 2015
Debt payments																				$ 100,000	$ 0
2019 Cherokee Loan and Security Agreement
Principal balance															$ 240,000		$ 220,000			0		$ 240,000		$ 240,000
Delinquent fee charged															8%
Loan amount																		$ 200,000
Interest expense																				4,000	11,000
Penalty																	$ 20,000
Annual interest rate on loan																		18%
Loan and Security Agreement with Cherokee Financial, LLC
Delinquent fee charged															8%
Loan amount																				0		1,000,000			$ 1,200,000
Interest expense																				13,000	25,000
Penalty															$ 100,000
Annual oversight fee percentage																1%
Fixed rate																10%
Principal amount															$ 1,000,000
Annual principal reduction payments																				75,000
Increased agreement extension amount																$ 1,000,000
Crestmark Line of Credit
Interest expense																				0	10,000
Initial term																			5 years
Payment for line of credit																							$ 34,000
November 2020 Term Loan
Interest expense																				1,000	1,000
Term Loan										$ 50,000										50,000		50,000
Loan interest rate										7%
Extended loan maturity										Feb. 04, 2021
SEPTEMBER 2022 HEALGEN LOAN & PROMISSORY NOTE [Member]
Loan interest rate														1%
Debt payments														$ 140,000
Increase in principal loan	$ 965,000	$ 815,000										$ 715,000	$ 700,000
Description of amendment	Under this fourth amendment, the amount of the first payment (due February 15, 2023) was changed to $337,000 with payments of the same amount due on March 15, 2023 and April 15, 2023	Under this third amendment, the amount of the first payment (due February 15, 2023) was changed to $286,000 with payments of the same amount due on March 15, 2023 and April 15, 2023										Under this second amendment, the amount of the first payment was changed to $251,000 with payments of the same amount due on March 15, 2023 and April 15, 2023	Under this first amendment, the loan maturity date was extended to April 15, 2023 and the first payment date was extended to February 15, 2023 and changed to $246,000
Promissory Note														40,000
Total amount														400,000
Payment for line of credit																				34,000
Net proceeds														360,000
Balance of Healgen loan																				0		715,000
Payment to healgen against due amount											$ 965,000
December 2021 Shareholder Loans
Interest expense																				4,000	$ 1,000
Loan interest rate									7%
Additional funds														40,000
Loan agreement amount			$ 225,000	$ 200,000	$ 175,000	$ 200,000	$ 125,000	$ 75,000	$ 75,000											$ 125,000		$ 225,000
Increase in principal loan			$ 25,000	$ 25,000		$ 75,000	$ 50,000	$ 25,000						$ 265,000
Principal reduction payment					$ 25,000

Employee Retention Credit (Deta

Employee Retention Credit (Details Narrative) - USD ($)		3 Months Ended	6 Months Ended
	Jun. 02, 2022	Mar. 31, 2021	Jun. 30, 2021	Mar. 31, 2023
Employee Retention Credit
Refund of wages	$ 199,000	$ 202,000	$ 198,000
Claimed as a refund amount	198,000
Refund as interest amount	$ 1,000
Refund Total				$ 202,000

Asset Sale to Healgen (Details

Asset Sale to Healgen (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended
	Feb. 28, 2023	Feb. 15, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Purchase price retention fund to cover potential indemnification claims	$ 300,000
Shares of common stock issued		27,863,899
Shares of common stock outstanding		47,098,476
Common stock par value		$ 0.01	$ 0.01		$ 0.01
Shares of common stock sales description		the Asset Sale to Healgen required the affirmative vote of the holders of a majority of the outstanding shares of the Company’s common stock (par value $0.01). 26,381,832, or 54.84% of the total outstanding shares of the Company, voted in favor of the Asset Sale to Healgen. 1,476,077, or 3.06% of the total outstanding shares, voted against the Asset Sale to Healgen. 5,990, or 0.01% of the total shares outstanding, withheld voting on the Asset Sale to Healgen.
Total consideration for sale of assets	3,000,000		$ (2,114,000)	$ 0
Net proceed	247,000
Net proceed from loans	965,000
Property related taxes	193,000
Current property related taxes	12,000
Cherokee LSA [Member]
Principal amount for interest	1,031,000
Cherokee Term Loan [Member]
Principal amount for interest	$ 252,000

Stock Options and Warrants (Det

Stock Options and Warrants (Details) - Equity Option [Member] - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Shares, beginning balance	1,736,000	1,937,000
Granted	0	0
Share exercised	0	0
Cancelled	46,000	0
Shares, ending balance	1,690,000	1,937,000
Option Exercisable qat end of quarter	1,690,000	1,937,000
Options outstanding at end of quarter Aggregate Intrinsic	$ 0	$ 0
Weighted average exercise price, beginning balance	0.12	0.13
Weighted average exercise price, cancelled/expired	0.26	0
Weighted average exercise price, ending balance	0.12	0.13
Weighted average exercise price, exercisable	$ 0.12	$ 0.13

Stock Options and Warrants (D_2

Stock Options and Warrants (Details Narrative) - Equity Option [Member] - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share based payment	$ 0	$ 0
Unrecognized share based payment expense related to stock options	$ 0

Changes in Stockholders Defic_2

Changes in Stockholders Deficit (Details Narrative) - LANDMARK CONSULTING AGREEMENT [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Restricted shares	500,000
Warrant to purchase	2,750,000
Gross proceeds	96,250,000,000
common shares | $ / shares	$ 0.035
Additional restricted shares	250,000
Initial restricted common stock shares	500,000

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Taxes
Tax expense at federal statutory rate	(21.00%)	(21.00%)
State tax expense, net of federal tax effect	0%	0%
Increase in valuation allowance	21%	21%
Effective income tax rate	0%	0%

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Income Taxes
Inventory allowance	$ 0	$ 61,000
Allowance for doubtful accounts	1,000	1,000
Stock based compensation	138,000	149,000
Deferred wages payable	30,000	21,000
Depreciation - property, plant and equipment	0	(19,000)
Research and development credits	26,000	24,000
Net operating loss carry-forward	2,482,000	2,972,000
Total gross deferred income tax assets	2,677,000	3,209,000
Less deferred income tax assets valuation allowance	(2,677,000)	(3,209,000)
Net deferred income tax assets	$ 0	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Income Taxes
Net deferred income tax assets valuation allowance	$ 2,677,000		$ 3,209,000
Valuation allowance, deferred tax asset, change in amount	532,000	$ 91,000
Research and development	26,000
Operating loss carryforwards	$ 11,427,000
Expire date	expire in 2022 and continue to expire through 2038
Carry overs Operating losses	100%
Carry overs Operating losses taxabale income percentage	80%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Apr. 17, 2023	Mar. 31, 2023
Consulting services, amount		$ 12,000
Deferred compensation		92,000
November 2020 Term Loan [Member]
Principal loan amount		50,000
Melissa Waterhouse [Member]
Principal loan amount		32,000
December 2021 Shareholder Loan [Member]
Principal loan amount		25,000
Balance due on Short term loan to shareholders		175,000
ERC Refund [Member]
ERC refund amount		$ 202,000
Subsequent Event [Member]
Payment received from IRS	$ 2,000
Payment received	$ 156,000